直接取栓与桥接治疗对急性大血管闭塞性缺血性卒中疗效比较的荟萃分析

doi:10.3969/j.issn.1673-5765.2022.07.008

摘要/Abstract

摘要：

目的比较急性大血管闭塞性缺血性卒中（acute ischemic stroke with large vessel occlusion，AIS-LVO）患者直接取栓治疗（direct endovascular thrombectomy，DEVT）和桥接治疗（bridging therapy，BT）的疗效和安全性。

方法检索1990年1月1日-2022年7月15日PubMed、Embase和Cochrane图书馆数据库已经发表的英文文献。纳入标准：在符合IVT条件（卒中发作时间≤4.5 h）的AIS-LVO患者中，应用随机临床试验（randomized controlled trial，RCT）或基线匹配分析的前瞻性观察性研究，比较DEVT与BT治疗的有效性和安全性。首要有效性终点为卒中发病90 d神经功能独立（mRS 0～2分），首要安全性终点是全因死亡率，其他终点包括症状性颅内出血（symptomatic intracerebral hemorrhage，sICH）发生率和血管成功再通率（TICI≥2b/3级）。主要有效性的非劣效性界值定义为RD的95%CI下限≥-6.5%。

结果共6项RCT研究（2334例）和5项前瞻性观察性研究（2947例）纳入荟萃分析。DEVT组2620例（49.6%），BT组2661例（50.4%）。对于首要有效性终点，DEVT的发病90 d神经功能独立性差于BT（44.4% vs. 47.6%），差异有统计学意义（RD -0.03，95%CI -0.06～-0.01）。DEVT组sICH发生率低于BT组（4.3% vs. 5.5%；RD -0.01，95%CI -0.02～-0.00），差异有统计学意义；两组全因死亡率（20.0% vs. 18.8%，RD 0.01，95%CI -0.01～0.03）和血管成功再通率（85.1% vs. 86.4%；RD -0.01，95%CI -0.04～0.01）比较，差异无统计学意义。

结论对于卒中发病后≤4.5 h的AIS-LVO患者，直接取栓对急性大血管闭塞性缺血性卒中的疗效差于桥接治疗，还需要进一步行RCT研究。

文章导读： 对于急性大血管闭塞性缺血性卒中，包括最近发表RCT研究的荟萃分析结果显示，如果选择-6.5%为界值，直接取栓疗效非劣效于桥接治疗；队列研究的荟萃分析结果显示，直接取栓疗效差于桥接治疗。

关键词: 急性缺血性卒中; 直接取栓; 桥接治疗; 非劣效性

Abstract:

Objective To compare the efficacy and safety of direct endovascular thrombectomy (DEVT) and bridging therapy (BT) for acute ischemic stroke (AIS) with large vessel occlusion (LVO).

Methods The literature involving the DEVT and BT for AIS-LVO were retrieved in the PubMed, Embase database and Cochrane library database from January 1, 1990 to July 15, 2022. The studies included randomized controlled trials (RCTs) or prospective observational studies enrolling the patients with AIS-LVO who were eligible for intravenous thrombolysis (IVT) (time from stroke onset ≤4.5 h). The efficacy and safety of DEVT and BT were compared. The primary efficacy outcome was 90-day functional independence, defined as a mRS score of 0-2, the primary safety outcome was all-cause mortality, the other endpoints were symptomatic intracranial hemorrhage (sICH), and successful vascular recanalization (defined as TICI 2b/3). The non-inferiority cutoff for primary validity was defined as the lower limit of 95%CI for RD ≥-6.5%.

Results Finally, six RCTs (n=2334) and five observational prospective trials (n=2947) were included in the meta-analysis. There were 2620 patients (49.6%) in DEVT group and 2661 (50.4%) in BT group. The primary efficacy endpoint in DEVT group was inferior to that in BT group (44.4% vs. 47.6%, RD -0.03, 95%CI -0.06--0.01). The incidence of sICH in DEVT group was lower than that in BT group (4.3% vs. 5.5%, RD -0.01, 95%CI -0.02--0.00); while there were no statistical differences in all-cause death (20.0% vs. 18.8%, RD 0.01, 95%CI -0.01-0.03), and the rate of successful recanalization (85.1% vs. 86.4%, RD -0.01, 95%CI -0.04-0.01) between the two groups.

Conclusions For patients with AIS-LVO within 4.5 hours from stroke onset, DEVT was inferior to BT and more RCTs were needed in the future.

Key words: Acute ischemic stroke; Direct thrombectomy; Bridging therapy; Non-inferiority

郑玮, 翟华筝, 陈萌萌, 汪敬业. 直接取栓与桥接治疗对急性大血管闭塞性缺血性卒中疗效比较的荟萃分析[J]. 中国卒中杂志, 2022, 17(07): 720-729.

ZHENG Wei, ZHAI Huazheng, CHEN Mengmeng, WANG Jingye. Efficacy and Safety of Direct Thrombectomy versus Bridging Therapy for Acute Ischemic Stroke: A Meta-Analysis[J]. Chinese Journal of Stroke, 2022, 17(07): 720-729.

参考文献

[1] POWERS W J，RABINSTEIN A A，ACKERSON T，et al. Guidelines for the early management of patients with acute ischemic stroke：2019 update to the 2018 guidelines for the early management of acute ischemic stroke：a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J/OL]. Stroke，2019，50（12）：e344-e418[2022-02-22]. https://doi.org/10.1161/STR.0000000000000211.

[2] LIU L P，CHEN W Q，ZHOU H Y，et al. Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders：executive summary and 2019 update of clinical management of ischaemic cerebrovascular diseases[J]. Stroke Vasc Neurol，2020，5（2）：159-176.

[3] BERKHEMER O A，FRANSEN P S，BEUMER D，et al. A randomized trial of intraarterial treatment for acute ischemic stroke[J]. N Engl J Med，2015，372（1）：11-20.

[4] CAMPBELL B C，MITCHELL P J，KLEINIG T J，et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection[J]. N Engl J Med，2015，372（11）：1009-1018.

[5] GOYAL M，DEMCHUK A M，MENON B K，et al. Randomized assessment of rapid endovascular treatment of ischemic stroke[J]. N Engl J Med，2015，372（11）：1019-1030.

[6] JOVIN T G，CHAMORRO A，COBO E，et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke[J]. N Engl J Med，2015，372（24）：2296-2306.

[7] SAVER J L，GOYAL M，BONAFE A，et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke[J]. N Engl J Med，2015，372（24）：2285-2295.

[8] BRACARD S，DUCROCQ X，MAS J L，et al. Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke（THRACE）：a randomised controlled trial[J]. Lancet Neurol，2016，15（11）：1138-1147.

[9] GOYAL M，MENON B K，VAN ZWAM W H，et al. Endovascular thrombectomy after large-vessel ischaemic stroke：a meta-analysis of individual patient data from five randomised trials[J]. Lancet，2016，387（10029）：1723-1731.

[10] YANG P F，ZHANG Y W，ZHANG L，et al. Endovascular thrombectomy with or without intravenous alteplase in acute stroke[J]. N Engl J Med，2020，382（21）：1981-1993.

[11] ZI W J，QIU Z M，LI F L，et al. Effect of endovascular treatment alone vs intravenous alteplase plus endovascular treatment on functional independence in patients with acute ischemic stroke：the DEVT randomized clinical trial[J]. JAMA，2021，325（3）：234-243.

[12] SUZUKI K，MATSUMARU Y，TAKEUCHI M，et al. Effect of mechanical thrombectomy without vs with intravenous thrombolysis on functional outcome among patients with acute ischemic stroke：the SKIP randomized clinical trial[J]. JAMA，2021，325（3）：244-253.

[13] BELLWALD S，WEBER R，DOBROCKY T，et al. Direct mechanical intervention versus bridging therapy in stroke patients eligible for intravenous thrombolysis：a pooled analysis of 2 registries[J]. Stroke，2017，48（12）：3282-3288.

[14] BROEG-MORVAY A，MORDASINI P，BERNASCONI C，et al. Direct mechanical intervention versus combined intravenous and mechanical intervention in large artery anterior circulation stroke：a matched-pairs analysis[J]. Stroke，2016，47（4）：1037-1044.

[15] TONG X，WANG Y L，FIEHLER J，et al. Thrombectomy versus combined thrombolysis and thrombectomy in patients with acute stroke：a matched-control study[J]. Stroke，2021，52（5）：1589-1600.

[16] WANG H，ZI W，HAO Y，et al. Direct endovascular treatment：an alternative for bridging therapy in anterior circulation large-vessel occlusion stroke[J]. Eur J Neurol，2017，24（7）：935-943.

[17] AHMED N，MAZYA M，NUNES A P，et al. Safety and outcomes of thrombectomy in ischemic stroke with vs without Ⅳ thrombolysis[J/OL]. Neurology，2021，97（8）：e765-e776[2022-02-22]. https://doi.org/10.1212/WNL.0000000000012327.

[18] MOHER D，LIBERATI A，TETZLAFF J，et al. Preferred reporting items for systematic reviews and meta-analyses：the PRISMA statement[J/OL]. PLoS Med，2009，6（7）：e1000097[2022-02-22]. https://doi.org/10.1371/journal.pmed.1000097.

[19] FISHER M，ALBERS G W，DONNAN G A，et al. Enhancing the development and approval of acute stroke therapies：Stroke Therapy Academic Industry roundtable[J]. Stroke，2005，36（8）：1808-1813.

[20] LIN C J，SAVER J L. Noninferiority margins in trials of thrombectomy devices for acute ischemic stroke：is the bar being set too low?[J]. Stroke，2019，50（12）：3519-3526.

[21] CRANSTON J S，KAPLAN B D，SAVER J L. Minimal clinically important difference for safe and simple novel acute ischemic stroke therapies[J]. Stroke，2017，48（11）：2946-2951.

[22] BURGOS A M，SAVER J L. Evidence that tenecteplase is noninferior to alteplase for acute ischemic stroke：meta-analysis of 5 randomized trials[J]. Stroke，2019，50（8）：2156-2162.

[23] FISCHER U，KAESMACHER J，STRBIAN D，et al. Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke：an open-label，blinded-outcome，randomised non-inferiority trial[J]. Lancet，2022，400（10346）：104-115.

[24] LECOUFFE N E，KAPPELHOF M，TREURNIET K M，et al. A randomized trial of intravenous alteplase before endovascular treatment for stroke[J]. N Engl J Med，2021，385（20）：1833-1844.

[25] MITCHELL P J，YAN B，CHURILOV L，et al. Endovascular thrombectomy versus standard bridging thrombolytic with endovascular thrombectomy within 4. 5 h of stroke onset：an open-label，blinded-endpoint，randomised non-inferiority trial[J]. Lancet，2022，400（10346）：116-125.

[26] KATSANOS A H，TURC G，PSYCHOGIOS M，et al. Utility of intravenous alteplase prior to endovascular stroke treatment：a systematic review and meta-analysis of RCTs[J/OL]. Neurology，2021，97（8）：e777-e784[2022-02-22]. https://doi.org/10.1212/WNL.0000000000012390.

[27] LIN C H，SAVER J L，OVBIAGELE B，et al. Endovascular thrombectomy without versus with intravenous thrombolysis in acute ischemic stroke：a non-inferiority meta-analysis of randomized clinical trials[J]. J Neurointerv Surg，2022，14（3）：227-232.

[28] PODLASEK A，DHILLON P S，BUTT W，et al. Direct mechanical thrombectomy without intravenous thrombolysis versus bridging therapy for acute ischemic stroke：a meta-analysis of randomized controlled trials[J]. Int J Stroke，2021，16（6）：621-631.

[29] JANG K M，CHOI H H，JANG M J，et al. Direct endovascular thrombectomy alone vs. bridging thrombolysis for patients with acute ischemic stroke：a meta-analysis[J/OL]. Clin Neuroradiol，2021[2022-02-22]. https://doi.org/10.1007/s00062-021-01116-z.

[30] CHEN Z J，LI X F，LIANG C Y，et al. Comparison of prior bridging intravenous thrombolysis with direct endovascular thrombectomy for anterior circulation large vessel occlusion：systematic review and meta-analysis[J/OL]. Front Neurol，2021，12：602370[2022-02-22]. https://doi.org/10.3389/fneur.2021.602370.

[31] SARRAJ A，GROTTA J，ALBERS G W，et al. Clinical and neuroimaging outcomes of direct thrombectomy vs bridging therapy in large vessel occlusion：analysis of the SELECT cohort study[J/OL]. Neurology，2021，96（23）：e2839-e2853[2022-02-22]. https://doi.org/10.1212/WNL.0000000000012063.

[32] NOGUEIRA R G，TSIVGOULIS G. Large vessel occlusion strokes after the DIRECT-MT and SKIP trials：is the alteplase syringe half empty or half full?[J]. Stroke，2020，51（10）：3182-3186.